Home › NDC Lookup › RxCUI directory › RxCUI 312301

Pentoxifylline 400 MG Extended Release Oral Tablet — RxCUI 312301

RxNorm drug concept · Semantic clinical drug
RxCUI 312301 Semantic clinical drug · SCD ● Current RxNorm concept 7 FDA products 17 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI312301
Official namePentoxifylline 400 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped7
Package NDCs mapped17
Reported Medicaid activity (SDUD)72,461 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pentoxifylline: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Pentoxifylline helps your blood flow more easily through the narrowed arteries in your legs. It makes your blood less thick and your red blood cells more flexible, so more oxygen c...
  • What exactly does pentoxifylline do for my legs?
  • You might start to notice some improvement in your walking ability within 2 to 4 weeks, but it's recommended to keep taking it for at least 8 weeks to get the full benefit. Studies...
  • How long will it take before I notice it working?
📖 Read our full Pentoxifylline guide →

🕸️ Concept Web — How Pentoxifylline 400 MG Extended Release Oral Tabl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pentoxifylline 400 MG Extended Release Oral Tablet RxCUI 312301

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pentoxifylline 8013
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pentoxifylline Extended Release Oral Tablet 373287
    • Pentoxifylline Oral Product 1165412
    • Pentoxifylline Pill 1165413
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Pentoxifylline 400 MG 316466

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pentoxifylline 400 MG SCDC · 316466
  • Pentoxifylline Extended Release Oral Tablet SCDF · 373287
  • Pentoxifylline Oral Product SCDG · 1165412
  • Pentoxifylline Pill SCDG · 1165413

📦 FDA Products & Package NDCs

7 products · 17 package NDCs
17 package NDCs map to RxCUI 312301 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00615-8511-39 30 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0615-8511-39) Pentoxifylline NCS HealthCare of KY, LLC dba Vangard Labs 2024-06-26
00904-5448-61 100 BLISTER PACK in 1 CARTON (0904-5448-61) / 1 TABLET, EXT... PENTOXIFYLLINE Major Pharmaceuticals 1999-06-10
16571-0856-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (16571-856-01) Pentoxifylline Rising Pharma Holdings, Inc. 2026-06-05
16571-0856-05 50 BLISTER PACK in 1 CARTON (16571-856-05) / 10 TABLET, EXT... Pentoxifylline Rising Pharma Holdings, Inc. 2026-06-05
16571-0856-11 10 BLISTER PACK in 1 CARTON (16571-856-11) / 10 TABLET, EXT... Pentoxifylline Rising Pharma Holdings, Inc. 2026-06-05
16571-0856-50 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (16571-856-50) Pentoxifylline Rising Pharma Holdings, Inc. 2026-06-05
16571-0856-90 1 BLISTER PACK in 1 CARTON (16571-856-90) / 10 TABLET, EXTE... Pentoxifylline Rising Pharma Holdings, Inc. 2026-06-05
60505-0033-06 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-0033-6) PENTOXIFYLLINE Apotex Corp. 1999-06-10
60505-0033-07 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (60505-0033-7) PENTOXIFYLLINE Apotex Corp. 1999-06-10
63629-2910-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63629-2910-1) PENTOXIFYLLINE Bryant Ranch Prepack 2005-08-09
63629-2910-02 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (63629-2910-2) PENTOXIFYLLINE Bryant Ranch Prepack 2024-12-06
63629-2910-03 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (63629-2910-3) PENTOXIFYLLINE Bryant Ranch Prepack 2023-10-11
70954-0668-10 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (70954-668-10) Pentoxifylline ANI Pharmaceuticals, Inc. 2024-01-15
70954-0668-20 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (70954-668-20) Pentoxifylline ANI Pharmaceuticals, Inc. 2024-01-15
71335-2586-01 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2586-1) Pentoxifylline Bryant Ranch Prepack 2025-04-07
71335-2586-02 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2586-2) Pentoxifylline Bryant Ranch Prepack 2025-04-07
71335-2586-03 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (71335-2586-3) Pentoxifylline Bryant Ranch Prepack 2025-04-07
Observed labelers: Bryant Ranch Prepack (6) · Rising Pharma Holdings, Inc. (5) · ANI Pharmaceuticals, Inc. (2) · Apotex Corp. (2) · Major Pharmaceuticals (1) · NCS HealthCare of KY, LLC dba Vangard Labs (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.2368
Range $0.2368–$0.2368 · middle 50% $0.2368–$0.2368 · 7 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.